Elisabeth Klager, Administrative Director, LBI Digital Health and Patient Safety

Elisabeth Klager has a business background with a focus on innovation and strategy management.

From 2014 to 2019 she worked in Vienna and Hamburg for an international health technology company in the field of business development for telemedicine and digital health solutions. In October 2019, she joined the board of the newly founded Ludwig Boltzmann Institute Digital Health and Patient Safety as Administrative Director, where she is also responsible for the research approach "Open Innovation in Science".

Elisabeth Klager is currently pursuing a PhD in telemedicine and empowerment at the Medical University of Vienna's Center for Public Health.

Eva Prieschl-Grassauer, Chief Scientific Officer, Marinomed​

Dr. Prieschl-Grassauer has more than ten years of experience working in pharmaceutical drug development. She is founder and owner of Marinomed, a biopharmaceutical company discovering and developing innovative naturally-derived immunological and antiviral treatments. Before Marinomed, she was head of the allergy program at Novartis in Vienna. In this position she also discovered the mechanism of action of FTY720 (Fingolimod), Novartis´ novel immunomodulatory drug against multiple sclerosis. Following that, she supervised the clinical development of an innovative cancer therapy drug that was in clinical phase III at that time.​

Dr. Prieschl-Grassauer has published more than 30 articles in high ranking peer-reviewed journals in the field of immunology, molecular biology and medicinal chemistry. ​

Eva Rohde, Head of Clinical Department of Transfusion Medicine, University Hospital Salzburg

Eva Rohde is Head of the Clinical Department of Transfusion Medicine at the University Hospital Salzburg and Director of the first academic pharmaceutical manufacturing unit for stem cell- and extracellular vesicle-based therapeutics in Europe.

She finished training in Transfusion Medicine in 2005 and acquired the postdoctoral lecturer qualification on stem cell research in 2009. Her research at the Paracelsus Medical University (PMU) in Salzburg focuses on the application of stem cell-based therapies with a special emphasis on their extracellular vesicles (EVs). She is involved in the EVTT (Extracellular Vesicles Theralytic Technologies) Transfer Center. EVTT focuses on theralytic technologies for nanovesiclular therapeutics with the overarching goal to develop novel cell-free therapies in conjunction with scientifically solid application-oriented analytical technologies. She actively contributes to a global network of academic and industrial partners who share the goal of the clinical development and assessment of EV-based therapies in diseases with a high unmet need.

Eva Rohde is CEO of the PMU Innovations GmbH and Chair of the global “Task Force on Regulatory Affairs and Clinical Use of EV-based Therapeutics” of the International Society for Extracellular Vesicles (ISEV). Recently, her work was highlighted in Nature.

Joachim Rothe, Partner, EQT Life Sciences ​

Joachim (JR) Rothe, PhD, joined EQT Life Sciences in 2002. His prime focus and responsibility within EQT is to invest in unlisted securities and the general management of the firm. Prior to joining EQT, Joachim was the Managing Director of MPM Capital Germany, a US healthcare investment firm, where he rose to head up their European investment franchise. Previously, he worked at McKinsey & Company in Germany and at Hoffmann-La Roche in Switzerland. Joachim brings a strong scientific background and in-depth knowledge of the pharmaceutical and biotechnology industries to the LSP team. He has been appointed a Director of a large number of companies, all of which he has helped to grow by leveraging his scientific expertise, pharmaceutical experience and global networks. Among others, Joachim is currently a Director at Atlas Genetics, a UK diagnostic company developing ultra-rapid point-of-care tests for a range of infectious diseases.​

Joachim obtained a Master’s degree in Biochemistry from the Free University in Berlin and a PhD in Molecular Immunology from Freiburg University. He has authored numerous articles in leading scientific publications, including Nature.​

Angelika Weinländer-Mölders, IMCD Deutschland GmbH​

Dr. Angelika Weinländer-Mölders has more than 15 years of experience in the medical equipment business with a generalist background and a sales and marketing focus. From 2009  to 2015 she was responsible as chief executive officer for Caesar & Loretz, a company in the pharmaceutical industry. Before Dr. Angelika Weinländer-Mölders was working for small, mid-sized and large companies in several positions as CEO, Business Unit Director or Commercial Director with a focus of establishing or re-structuring of internationally active business units.​

Dr. Angelika Weinländer-Mölders holds a Ph.D in Chemistry from the university Friderciana Karlsruhe.​